1. **Formulary Amendments and Additions**

|  |  |  |
| --- | --- | --- |
| **Name of Drug** | **RAG Rated** | **Information** |
| **Trelegy Ellipta**  (Trelegy Ellipta 92 micrograms/55 micrograms/22 micrograms inhalation powder, pre-dispensed) | **Green** | Trelegy Ellipta has been agreed to be included onto the formulary as GREEN status. Trelegy Ellipta is a triple dry powder inhaler device indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist |
| **Enstilar**  (Enstilar 50 micrograms/g + 0.5 mg/g cutaneous foam) | **Amber** | APC has agreed to include Enstilar onto the formulary as AMBER with no shared care, provided that the guidelines were adhered to. Enstilar is indicated for the treatment of psoriasis in adults. |
| **Entresto** | **Red** | RED status until a shared care guideline is approved. |
| **Tamoxifen** | **Red** | APC have agreed to list Tamoxifen as RED for the reduction of breast cancer as this is an unlicensed indication GPs should not be expected to prescribe it |

**2) NICE Technical Appraisals**

|  |  |  |
| --- | --- | --- |
| **NICE TA** | **Indication** | **RAG rating** |
| NICE TA521 | Guselkumab for treating moderate to severe plaque psoriasis | RED |
| NICE TA522 | Pembrolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable | RED |
| NICE TA523 | Midostaurin for untreated acute myeloid leukaemia | RED |
| NICE TA524 | Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma | RED |
| NICE TA525 | Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum containing chemotherapy | RED |
| NICE TA526 | Arsenic trioxide for treating acute promyelocytic leukaemia | RED |
| NICE TA217 | Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease | RED |
| NICE TA527 | Beta interferons and glatiramer acetate for treating multiple sclerosis | RED |
| NICE TA528 | Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer | RED |
| NICE TA529 | Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer | RED |
| NICE TA530 | Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy | RED |
| NICE TA531 | Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer | RED |
| NICE TA532 | Cenegermin for treating neurotrophic keratitis | RED |
| NICE TA533 | Ocrelizumab for treating relapsing–remitting multiple sclerosis | RED |
| NICE TA492 | Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable | RED |
| NICE TA493 | Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable | RED |
| NICE TA534 | Dupilumab for treating moderate to severe atopic dermatitis | RED |

**3) Items Approved at APC**

Rheumatology Shared Care Guidelines   
The following shared care guidelines were approved:

* Prescribing Framework for Azathioprine in Rheumatic Diseases
* Prescribing Framework for Injectable Gold (Sodium Aurothiomalate) in Rheumatic Disease
* Prescribing Framework for Hydroxychloroquine in Rheumatic Disease
* Prescribing Framework for Sulfasalazine in Rheumatic Disease
* Prescribing Framework For Leflunomide in Rheumatic Disease

In practical terms the shared care guidelines will be initially published on the Northern Lincolnshire and Goole trust intranet. Ensuring correct blood test forms are in place and ready to use prior to going live.

**4) MHRA Alerts**

The latest MHRA Alerts are published here: [www.gov.uk/government/publications/drug-safety-update-monthly-newsletter](http://www.gov.uk/government/publications/drug-safety-update-monthly-newsletter)

**5) Net Formulary update**

We are continuing to update our Formulary available at: [www.apcnlgformulary.nhs.uk](http://www.apcnlgformulary.nhs.uk)

Net Formulary holds information about drugs and their formulary status. It also includes traffic light status of medications so that prescriber responsibilities are clear. Pathways, NICE and APC policies will be linked to this as well as APC minutes and policies. This is an active document which is being continually updated. Please feel free to provide feedback or comments to the Area Prescribing Professional secretary Aliya Turk at [aliya.turk@nhs.net](mailto:aliya.turk@nhs.net)